Antibody drug conjugates against the receptor for advanced glycation end products (RAGE), a novel therapeutic target in endometrial cancer.

Gareth D HealeyBelen Pan-CastilloJezabel Garcia-ParraJulia DaviesShaun RobertsEilir JonesKalyan DharSarika NandananNasima TofazzalLuke PiggottRichard ClarksonGillian SeatonAsa FrostellTim FaggeColin McKeeLavinia MargaritR Steven ConlanDeyarina Gonzalez

Published in: Journal for immunotherapy of cancer (2019)

These data, together with important design considerations implied by the present study, suggest RAGE-ADCs could be translated to novel therapeutics for EC patients.

Keyphrases

endometrial cancer
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis
prognostic factors
small molecule
electronic health record
big data
drug delivery